Article content

Complete Response Letter [CRL]

The FDA sends a complete response letter (also known as a CRL) to communicate it has completed its review of a new or generic drug application, and it decided that it will not approve it for marketing in its present form. Receiving a CRL from the FDA is not good news and a stock will likely drop as a result.

<< Back to Glossary Index

Picture of SOFI artificial intelligence

SOFI AI For Premium Members